Evidence map›Paper›PMID 42538474›Full record

ArticleClinical rheumatology2026

Diagnostic delay in psoriatic disease: cutaneous and musculoskeletal pathways in a Mexican tertiary-care cohort.

Guillermo Arturo Guaracha-Basañez, Irazú Contreras-Yáñez, Silvia Méndez-Flores, Raúl Pérez-Gamboa, Iris Paola García-Herrera, Virginia Pascual-Ramos

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Guillermo Arturo Guaracha-BasañezDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID http://orcid.org/0000-0001-8060-7301
Irazú Contreras-YáñezDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Silvia Méndez-FloresDepartment of Dermatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Raúl Pérez-GamboaDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Iris Paola García-HerreraDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Virginia Pascual-RamosDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. virtichu@gmail.com.ORCID http://orcid.org/0000-0002-7368-498X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPsoriatic disease (PsD) is frequently diagnosed late. Understanding its cutaneous and musculoskeletal diagnostic pathways is crucial for improving early recognition.

objectivesTo describe and compare the cutaneous and musculoskeletal diagnostic pathways in patients with PsD, identify factors associated with diagnostic delay, and analyze trends in time to diagnosis by pathway.

methodsCross-sectional study using a structured questionnaire. Time to diagnosis was defined separately for the cutaneous and musculoskeletal pathways, from symptom onset to the first physician-confirmed diagnosis of psoriasis (Pso) or psoriatic arthritis (PsA). Diagnostic delay was defined as time to diagnosis > 12 months. Logistic and linear regression models assessed associated factors and temporal trends.

resultsWe included 143 patients with PsD: 54 had Pso without PsA at cohort entry, and 89 had rheumatologist-confirmed PsA. Median time to diagnosis was 12.2 months in both pathways; diagnostic delay occurred in 58% of the cutaneous and 61.8% of the musculoskeletal pathways. In the cutaneous pathway, longer time to seek care increased the odds of delay, whereas a correct diagnosis at the first visit was protective. In the musculoskeletal pathway, older age and longer time to seek care increased the odds of delay, while specialist evaluation and DMARD initiation at first visit were protective. A more recent calendar year of symptom onset was associated with shorter time to diagnosis in both pathways.

conclusionsDiagnostic delays in PsD persist despite recent improvements. Distinct determinants across the cutaneous and musculoskeletal pathways highlight the need for earlier Pso recognition and more efficient referral for musculoskeletal symptoms suggestive of PsA. Keypoints • In this tertiary PsD cohort, the median time to diagnosis was 12 months in both the cutaneous and musculoskeletal diagnostic pathways, and more than half of the patients experienced delays >12 months. • In the cutaneous pathway, the main driver of delay was the time patients waited before seeking medical attention for skin lesions, whereas correct diagnosis at the first visit was protective. • In the musculoskeletal pathway, older age and delayed consultation for musculoskeletal symptoms were associated with longer delays, whereas early specialist assessment and DMARD initiation characterized more efficient pathways. • Time to diagnosis decreased significantly across calendar years in both pathways, although the persistently high delay burden underscores the need for stronger coordination among primary care, dermatology, and rheumatology.

Indexed as

Arthritis, PsoriaticDelayed DiagnosisPsoriasisAdultCross-Sectional StudiesFemaleHumansLogistic ModelsMaleMexicoMiddle AgedSurveys and QuestionnairesTertiary Health CareTreatment DelayDiagnostic delayLatin AmericaMultidisciplinary carePsoriasisPsoriatic arthritisReferral pathway

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.